Celcuity, Inc. (NASDAQ:CELC) Receives $105.25 Average Price Target from Brokerages

Shares of Celcuity, Inc. (NASDAQ:CELC) have received a consensus rating of “Moderate Buy” from the ten brokerages that are covering the company, MarketBeat.com reports. One analyst has rated the stock with a sell recommendation, one has issued a hold recommendation, seven have assigned a buy recommendation and one has issued a strong buy recommendation on the company. The average twelve-month price objective among brokerages that have issued ratings on the stock in the last year is $105.25.

CELC has been the topic of several recent research reports. Wolfe Research assumed coverage on Celcuity in a research note on Tuesday, November 18th. They issued an “outperform” rating and a $110.00 price objective on the stock. Wells Fargo & Company assumed coverage on shares of Celcuity in a research report on Friday, December 12th. They issued an “overweight” rating and a $126.00 price target for the company. Jefferies Financial Group lifted their target price on shares of Celcuity from $108.00 to $134.00 and gave the company a “buy” rating in a research note on Tuesday, December 2nd. Weiss Ratings reissued a “sell (d-)” rating on shares of Celcuity in a report on Wednesday, January 21st. Finally, HC Wainwright reaffirmed a “neutral” rating and issued a $94.00 price objective (up previously from $77.00) on shares of Celcuity in a research note on Monday, November 17th.

Celcuity Trading Up 2.8%

Celcuity stock opened at $117.25 on Friday. Celcuity has a 52-week low of $7.57 and a 52-week high of $120.32. The company has a market cap of $5.43 billion, a P/E ratio of -31.95 and a beta of 0.25. The company has a quick ratio of 12.26, a current ratio of 12.26 and a debt-to-equity ratio of 2.74. The business has a 50-day simple moving average of $103.23 and a two-hundred day simple moving average of $70.48.

Celcuity (NASDAQ:CELC) last announced its earnings results on Wednesday, November 12th. The company reported ($0.92) EPS for the quarter, beating analysts’ consensus estimates of ($1.05) by $0.13. Analysts predict that Celcuity will post -2.62 EPS for the current year.

Insider Buying and Selling at Celcuity

In related news, Director Richard E. Buller sold 3,900 shares of the firm’s stock in a transaction on Thursday, November 20th. The shares were sold at an average price of $96.73, for a total transaction of $377,247.00. Following the completion of the transaction, the director directly owned 7,260 shares of the company’s stock, valued at approximately $702,259.80. This trade represents a 34.95% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Corporate insiders own 15.78% of the company’s stock.

Hedge Funds Weigh In On Celcuity

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Zurcher Kantonalbank Zurich Cantonalbank purchased a new position in Celcuity during the 4th quarter valued at approximately $551,000. Ogorek Anthony Joseph NY ADV increased its position in Celcuity by 19.7% in the fourth quarter. Ogorek Anthony Joseph NY ADV now owns 662 shares of the company’s stock worth $66,000 after purchasing an additional 109 shares during the last quarter. Tema Etfs LLC raised its stake in Celcuity by 7.9% during the fourth quarter. Tema Etfs LLC now owns 27,818 shares of the company’s stock valued at $2,775,000 after purchasing an additional 2,028 shares in the last quarter. Saxony Capital Management LLC bought a new position in Celcuity during the fourth quarter valued at $251,000. Finally, Hennion & Walsh Asset Management Inc. grew its stake in shares of Celcuity by 11.4% in the 4th quarter. Hennion & Walsh Asset Management Inc. now owns 190,933 shares of the company’s stock worth $19,044,000 after buying an additional 19,579 shares in the last quarter. 63.33% of the stock is owned by institutional investors.

Celcuity Company Profile

Celcuity, Inc is a clinical-stage biotechnology company specializing in precision oncology diagnostics. The company develops and commercializes predictive biomarker assays designed to identify which patients are most likely to benefit from targeted cancer therapies. By integrating functional profiling of tumor cells with molecular analyses, Celcuity seeks to optimize treatment selection and improve outcomes for patients with solid tumors.

Celcuity’s proprietary platform evaluates tumor cell sensitivity to various therapeutic agents using ex vivo assays that measure DNA damage response and other critical pathways.